NPs Basic Information

Name
Mycophenolic acid
Molecular Formula C17H20O6
IUPAC Name*
(E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
SMILES
CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O
InChI
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
InChIKey
HPNSFSBZBAHARI-RUDMXATFSA-N
Synonyms
mycophenolic acid; 24280-93-1; Mycophenolate; Myfortic; Melbex; Mycophenolsaeure; 483-60-3; Lilly-68618; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; NSC-129185; Acido micofenolico; Micofenolico acido; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; Acide mycophenolique; Acidum mycophenolicum; CCRIS 5565; NSC 129185; Ly 68618; (E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; MFCD00036814; Lilly 68618; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)-; CHEMBL866; HU9DX48N0T; 6-(1,3-Dihydro-7-hydroxy-5-methoxy-4-methyl-1-oxoisobenzofuran-6-yl)-4-methyl-4-hexanoic acid; CHEBI:168396; TNP00198; RS-61443 [AS MOFETIL]; NSC129185; 4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)-; 4-Methyl-5-methoxy-7-hydroxy-6-(5-carboxy-3-methylpent-2-en-1-yl)-phthalide (E)-; 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methylhex-4-enoic acid; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid (E)-; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)-; NCGC00016786-01; CAS-24280-93-1; Mycophenolic acid 100 microg/mL in Acetonitrile; 6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid; DSSTox_CID_21070; DSSTox_RID_79619; DSSTox_GSID_41070; Mycophenoic acid; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-4-hexenoic acid; Micofenolico acido [Spanish]; (4E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic Acid (Mycophenolic Acid); (E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid; 4-Hexenoic acid,6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)-; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoic acid; MOA; SMR000471887; Acido micofenolico [INN-Spanish]; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid; Acide mycophenolique [INN-French]; Acidum mycophenolicum [INN-Latin]; SR-01000597602; EINECS 246-119-3; UNII-HU9DX48N0T; mycophenolic-acid; Prestwick_817; EINECS 207-595-8; Mycophenolic acid [USAN:INN:BAN]; Tocris-1505; (Z)-Mycophenolic Acid; 1jr1; starbld0040186; Mycophenolic acid (TN); Prestwick2_000556; Prestwick3_000556; Spectrum5_001654; Mycophenolic Acid (MPA); UPCMLD-DP028; 4-Hexenoic acid, (E)-; EC 246-119-3; Mycophenolate;RS-61443; SCHEMBL4549; Mycophenolic (Mycophenolate); Mycophenolic acid, >=98%; BSPBio_000631; BSPBio_002534; MYCOPHENOLATE [VANDF]; MLS001074701; MLS002222265; MLS002695945; BIDD:GT0456; SPECTRUM1500674; MYCOPHENOLIC ACID [MI]; BPBio1_000695; GTPL6832; MEGxm0_000120; Mycophenolic acid (USAN/INN); Myfortic (mycophenolate sodium); SCHEMBL2514376; ZINC1758; MYCOPHENOLIC ACID [INN]; DTXSID4041070; MYCOPHENOLIC ACID [USAN]; UPCMLD-DP028:001; ACon0_000960; ACon1_000496; BDBM19264; CHEBI:92545; HMS500H08; EX-A975; MYCOPHENOLIC ACID [VANDF]; MYCOPHENOLIC ACID [MART.]; HMS1569P13; HMS1921A18; HMS2089A17; HMS2092G22; HMS2096P13; HMS2268H22; HMS3403P09; HMS3412F09; HMS3676F09; Pharmakon1600-01500674; MYCOPHENOLIC ACID [WHO-DD]; ACT02623; AMY40494; BCP05321; HY-B0421; Tox21_110610; BBL034696; CCG-39914; HB3987; NSC757424; s2487; STL419986; Mycophenolic acid, analytical standard; AKOS015888214; Tox21_110610_1; AC-4491; BCP9000970; DB01024; DS-1638; MYCOPHENOLIC ACID [ORANGE BOOK]; NSC-757424; SDCCGMLS-0066618.P001; (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-isobenzofuran-5-yl)-4-methyl-hex-4-enoic acid; IDI1_000146; NCGC00016786-02; NCGC00016786-03; NCGC00016786-04; NCGC00016786-05; NCGC00016786-06; NCGC00016786-07; NCGC00016786-08; NCGC00016786-09; NCGC00016786-10; NCGC00016786-11; NCGC00016786-12; NCGC00016786-15; NCGC00025190-01; NCGC00025190-02; NCGC00025190-03; NCGC00025190-04; NCGC00025190-05; NCGC00025190-07; NCGC00025190-08; NCGC00025190-09; NCGC00025190-10; (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxohydroisobenzofuran-5-yl)-4-methylhex -4-enoic acid; BM164624; Mycophenolic Acid - CAS 24280-93-1; SBI-0051945.P003; A-249; M2216; SW196951-2; C20380; D05096; EN300-122327; M 5255; M02087; AB00052466-13; AB00052466-14; AB00052466_15; AB00052466_16; EN300-1273238; 280M931; A817192; Mycophenolate mofetil impurity, mycophenolic acid-; Q420553; SR-01000597602-1; SR-01000597602-3; SR-01000597602-4; BRD-K63750851-001-06-6; BRD-K63750851-001-13-2; MYCOPHENOLATE MOFETIL IMPURITY F [EP IMPURITY]; Z2315575694; MYCOPHENOLATE MOFETIL IMPURITY, MYCOPHENOLIC ACID- [USP IMPURITY]; Mycophenolic acid, powder, BioReagent, suitable for cell culture, >=98%; 6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid;NSC 129185; 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthanlanyl)-4-methyl-4-hexanoic acid; (E)-6-(1,3-dihydro-4-hydroxy-6- methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid; (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxoisobenzofuran-5-yl)-4-methyl-4-hexenoic acid; 1162256-90-7; 4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (4E)- (9CI); 4-Hexenoic acid, 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-, (E)- (8CI); 4-Hexenoic acid,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5- isobenzofuranyl)-4-methyl-, (E)-; 4-Methyl-6-[3-oxo-7-methyl-4-hydroxy-6-methoxy-1,3-dihydroisobenzofuran-5-yl]-4-hexenoic acid; E-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid
CAS 24280-93-1
PubChem CID 446541
ChEMBL ID CHEMBL866
*Note: the IUPAC Name was collected from PubChem.
Chemical Classification:
  • Kingdom: Organic compounds
    • Superclass: Organoheterocyclic compou
      • Class: Isocoumarans
        • Subclass: Isobenzofuranones
          • Direct Parent: Phthalides

ClassyFire Version 1.0
PMID:27867422

NPs Species Source

Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference
Endophyte ID Endophyte Name Family Genus Taxonomy ID GenBank ID Closest GenBank ID Reference

NPs Content

*Note: The vaules in Content Percentage are calculated by dividing the content value by the maximum content value in NP Content.
**Note: The units with different NP content, due to their incomparable values, are separated into different tables.

NPs Biological Activity

Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name
Bioactivity Name Target ID Target Name Target Type Target Organism Target Organism ID Potency of Bioactivity Activity Type Value Unit Endophyte ID Endophyte Name

NPs Physi-Chem Properties

Molecular Weight: 320.3 ALogp: 3.2
HBD: 2 HBA: 6
Rotatable Bonds: 6 Lipinski's rule of five: Accepted
Polar Surface Area: 93.1 Aromatic Rings: 2
Heavy Atoms: 23 QED Weighted: 0.615

NPs ADMET Properties*

ADMET: Absorption

Caco-2 Permeability: -5.256 MDCK Permeability: 0.00000951
Pgp-inhibitor: 0.001 Pgp-substrate: 0.162
Human Intestinal Absorption (HIA): 0.029 20% Bioavailability (F20%): 0.015
30% Bioavailability (F30%): 0.002

ADMET: Distribution

Blood-Brain-Barrier Penetration (BBB): 0.004 Plasma Protein Binding (PPB): 96.21%
Volume Distribution (VD): 0.211 Fu: 2.22%

ADMET: Metabolism

CYP1A2-inhibitor: 0.068 CYP1A2-substrate: 0.642
CYP2C19-inhibitor: 0.017 CYP2C19-substrate: 0.058
CYP2C9-inhibitor: 0.071 CYP2C9-substrate: 0.731
CYP2D6-inhibitor: 0.048 CYP2D6-substrate: 0.169
CYP3A4-inhibitor: 0.01 CYP3A4-substrate: 0.037

ADMET: Excretion

Clearance (CL): 5.918 Half-life (T1/2): 0.901

ADMET: Toxicity

hERG Blockers: 0.003 Human Hepatotoxicity (H-HT): 0.126
Drug-inuced Liver Injury (DILI): 0.047 AMES Toxicity: 0.005
Rat Oral Acute Toxicity: 0.637 Maximum Recommended Daily Dose: 0.032
Skin Sensitization: 0.412 Carcinogencity: 0.68
Eye Corrosion: 0.004 Eye Irritation: 0.408
Respiratory Toxicity: 0.056
*Note: the ADMET properties was calculated by ADMETlab 2.0. Reference: PMID: 33893803.

Similar Compounds*

Compounds similar to EMNPD with top10 similarity:

Similar NPs Similar Drugs
NPs ID NPs 2D Structure Similarity Score TTD ID Drug 2D Structure Similarity Score
ENC001919 0.522 D04FBR 0.620
ENC005913 0.500 D0WY9N 0.271
ENC004362 0.500 D00FSV 0.234
ENC004504 0.478 D06VNK 0.224
ENC005914 0.458 D0YH0N 0.216
ENC002722 0.457 D0Y7ZD 0.214
ENC005336 0.419 D0R1RS 0.213
ENC003029 0.414 D0O4GY 0.211
ENC003354 0.397 D07MEH 0.208
ENC003016 0.394 D04UTT 0.207
*Note: the compound similarity was calculated by RDKIT.